FRNK, or Focal adhesion kinase-related nonkinase, is a fascinating protein that plays a critical role in cellular mechanics, particularly in processes related to cell adhesion and migration. This intriguing protein emerges from the alternative splicing of the Focal adhesion kinase (FAK) gene, which is known for its involvement in the integrin signaling pathways and the coordination of cellular responses to the physical and chemical cues of the extracellular matrix. Unlike its kinase-active counterpart, FRNK lacks the kinase domain and acts as a natural inhibitor or modulator of FAK by competing for substrates and binding partners. The expression of FRNK is tightly regulated within the cell, reflecting its significant role in modulating the dynamics of cell movement and signaling. The balance between FAK and FRNK is crucial for maintaining cellular homeostasis, and the perturbation of this balance can lead to alterations in the cellular framework and function.
The investigation into the regulation of FRNK expression is an area of considerable interest, given its central role in cellular function. Various chemical compounds have been identified that could potentially upregulate the expression of FRNK through a myriad of intracellular pathways. These activators might work by engaging with different signaling cascades, which in turn could lead to an increase in FRNK transcription or stabilization. For example, an inhibitor targeting the TGF-β pathway might inadvertently lead to the upregulation of FRNK as the cell attempts to recalibrate its adhesive properties. Similarly, a compound that interferes with the PDGF signaling could initiate a compensatory response that elevates FRNK expression to sustain cellular migration and stability. Other potential activators could include inhibitors of MEK or PI3K pathways, which might increase FRNK expression as part of the cell's effort to maintain its proliferative and survival mechanisms. It is the intricacies of these signaling networks and the cell's adaptive responses that underscore the potential for certain compounds to act as indirect upregulators of FRNK. Understanding the cellular context and the complex interplay of intracellular signals is imperative for elucidating the mechanisms by which these chemical compounds could influence FRNK expression.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB 431542, as an inhibitor of TGF-β signaling, could lead to an increase in FRNK by attempting to maintain cellular adhesive interactions when TGF-β is suppressed. | ||||||
Imatinib mesylate | 220127-57-1 | sc-202180 sc-202180A | 25 mg 100 mg | $44.00 $109.00 | 61 | |
Imatinib mesylate targets the PDGF receptor, potentially resulting in the upregulation of FRNK as cells adapt to the altered PDGF-mediated signaling. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $28.00 $80.00 $412.00 $1860.00 $2962.00 | 5 | |
By targeting MEK1/2, Selumetinib may indirectly stimulate FRNK expression as a compensatory response to disrupted MAPK/ERK pathway activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 is a PI3K inhibitor that might prompt an increase in FRNK expression due to adaptive responses to impeded PI3K/AKT signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
As an mTOR inhibitor, Rapamycin could induce FRNK expression by eliciting a cellular response to the hampered mTOR signaling, which is critical for cell growth. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Targeting Src family kinases, Dasatinib could stimulate the synthesis of FRNK as cells adjust adhesion and migration processes in response to inhibited Src activity. | ||||||
Stat3 inhibitor V, stattic | 19983-44-9 | sc-202818 sc-202818A sc-202818B sc-202818C sc-202818D sc-202818E sc-202818F | 25 mg 100 mg 250 mg 500 mg 1 g 2.5 g 5 g | $127.00 $192.00 $269.00 $502.00 $717.00 $1380.00 $2050.00 | 114 | |
Stattic, known to inhibit STAT3, could lead to the upregulation of FRNK as the cell reorganizes its signaling pathways to compensate for the reduced STAT3 activity. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
BAY 11-7082, by inhibiting NF-kB, could potentially trigger the upregulation of FRNK as part of the cellular response to changes in survival and inflammation signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibition of JNK by SP600125 may lead to an elevation in FRNK expression as a cellular adaptation to stress response pathway alterations. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
Tunicamycin can induce ER stress, which might result in an upregulation of FRNK as the cell engages mechanisms to manage protein folding and stress conditions. |